UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 30, 2014

BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-23186 (Commission File Number) 62-1413174 (IRS Employer Identification No.)

4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 (Address of Principal Executive Offices)

(919) 859-1302 (Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

	appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following (see General Instruction A.2 below):
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
П	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240 13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On May 30, 2014, BioCryst Pharmaceuticals, Inc. (the "Company") and the U.S. Department of Health and Human Services ("HHS") mutually agreed to amend the Agreement dated January 3, 2007 between the Company and HHS (the "Agreement") to extend the Agreement's current expiration date of May 31, 2014 for 30 days. The new expiration date is changed to June 30, 2014. All other terms and conditions of the Agreement remain unchanged.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

Amendment #20 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated May 30, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 5, 2014 BioCryst Pharmaceuticals, Inc.

By: /s/ Alane Barnes

Alane Barnes

Vice President, General Counsel, and Corporate Secretary

EXHIBIT INDEX

Exhibit No.	Description
10.1	Amendment #20 to the Agreement between BioCryst Pharmaceuticals. Inc. and the U.S. Department of Health and Human Services, dated May

30, 2014.

AMENDMENT OF SOLICI	TATION/MODIFICATION (OF CONTRACT	1. CONTRACT ID CO	1		
2. AMENDMENT/MODIFICATION NO.	3. EFFECTIVE DATE	4. REQUISITION/PURCH	ASE REO NO	5. PROJECT NO. (If applicable)		
0020	See Block 16C	N/A	AGE NEW. NO.	3. PROJECT NO. (Ir applicable)		
6. ISSUED BY	CODE ASPR-BARDA	7. ADMINISTERED BY (III	other than Item 6)	CODE ASPR-BARDA01		
ASPR-BARDA 330 INDEPENDENCE AVE SW ROOM 644-G WASHINGTON DC 20201	ASPR-BARDA 330 INDEPENDENCE AVE SW RM G644 WASHINGTON DC 20201					
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)			T OF SOLICITATION		
BIOCRYST PHARMACEUTICAL: 4505 EMPEROR BOULEVARD, S DURHAM, NC 27703			98. DATED (SEE 10A. MODIFICAT HHSO10020 10B. DATED (SE	TION OF CONTRACT/ORDER NO.		
CODE	FACILITY CODE		01/03/2007			
	THIS ITEM ONLY APPLIES TO	AMENDMENTS OF SO				
CHECK ONE A. THIS CHANGE ORDER IS IN ITEM 10A. B. THE ABOVE NUMBERED COME, etc.) SET FORTH IN ITEM 10A. C. THIS SUPPLEMENTAL AGE	POPENING HOUR AND ADDITION OF THE AUTHORITE TO ME AND ADDITION OF THE CONTRACT/OR SSUED PURSUANT TO: (Specify authorities) AND ADDITION OF THE AUTHORITE AUT	ODIFICATION OF COM RDER NO. AS DESCRI (ry) THE CHANGES SET FOR EFLECT THE ADMINISTRATIV TY OF FAR 43.103(b).	ITRACTS/ORDER BED IN ITEM 14. TH IN ITEM 14 ARE MA	S. DE IN THE CONTRACT ORDER NO.		
- BILATERAL MODIFIC	BILATERAL MODIFICATION AT THE MUTUAL AGREEMENT OF THE PARTIES D. OTHER (Specify type of modification and authority)					
E. IMPORTANT: Contractor is	not, 🔀 is required to sign this	document and return	1 copie	s to the issuing office.		
14. DESCRIPTION OF AMENDMENT/MODIFIC This Contract's expiration date is Except as provided herein, all terms and conditions. NAME AND TITLE OF SIGNER (Type or p.	changed by 30 days from Ma	ay 31, 2014 to June 3	0, 2014.	and in full force and effect.		
158. CONTRACTOR/OFFEROR	15C. DATE SIGNED	16B. UNITED STATES OF A	MERICA	16C, DATE SIGNED		
(Signature of person authorized to	sign)	(Signature	of Contracting Officer)			

NSN 7540-01-152-8070 Previous edition unusable STANDARD FORM 30 (REV. 10-83) Prescribed by GSA FAR (48 CFR) 53.243